Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied DNA Sciences, Inc. (APDN) CEO Jim Hayward on Q1 2020 Results - Earnings Call Transcript

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2019 Results - Earnings Call Transcript

A share offering Wednesday sent Applied DNA Sciences Inc. (NASDAQ: APDN) stock back down, giving back a huge one-day gain that followed news of a breakthrough in its leather tracking technology.

Applied DNA Stock Plunges After Share Offering Announcement

Shares of Applied DNA Sciences Inc. plummeted 72% to pace all Nasdaq losers on Wednesday, after the the company announced the pricing of a public offering of stock and warrants, the day after the stock rocketed more than 4-fold.

Applied DNA's stock plunges as stock and warrant offering comes a day after a 4-fold rally

Shares of Applied DNA Sciences Inc (NASDAQ: APDN) surged by more than 300% Tuesday after the company announced it has been successful at using a unique "DNA tag" to mark leather so it can be traced through the supply chain for more reliable proof of origin.

Applied DNA Stock Surges On DNA Leather Tagging News; Offering Expected Wednesday

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2019 Results - Earnings Call Transcript

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2019 Results - Earnings Call Transcript

The latest play on the booming global cannabis market may not be a cannabis company at all.

Biotech Stock Applied DNA Sciences Jumps 50% On Cannabis Deal

News for Applied DNA Sciences Stock (APDN)